Search
EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe
The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.
Read moreEHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials
EHA has responded to the EMA’s call for comments on the reflection paper on February 15.
Read moreJoin EHA and SEHH and receive up to €70 of combined discount on both memberships.
In 2018 the first joint membership was introduced between the Sociedad Española de Hematología y Hemotherapia (SEHH) and EHA which resulted in a closer cooperation in various areas. This joint membership will continue.
Read moreDates and deadlines
You may find in this page all the dates and deadlines related to the EHA2025 Hybrid Congress. All deadlines, except if mentioned differently, end at 23:59 CET/CEST.
The timelines will be updated regularly.
The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders
The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…
Read moreIn Memoriam Jean Claude Brouet
Professor Jean Claude Brouet passed away on December 12, 2022 at the age of 80.
Read moreMulti-center acute myeloid leukemia study update, December 2023
A project update from Prof Maria Teresa Voso. We successfully completed the data collection and harmonization phases, and are now in the process of data analysis.
Read more“Who dares wins,” - Elizabeth Macintyre, woman in hematology/EHA volunteer
Elizabeth Macintyre is currently EHA Board Secretary. She got her MD/PhD is Britain, her PhD in France and post-doc in America.
Read moreTargeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- »